Browse all articles

Home Get the app

Brand-quality audit Published Sep 28, 2025 Recalibrated Jun 14, 2026

XYMOGEN

Premium practitioner-grade supplements with strong testing and formulation signals, tempered by old regulatory history and request-based transparency.

XYMOGEN brand audit

Composite trust

80 /100 Strong

XYMOGEN scores like a premium practitioner brand with strong current quality/formulation signals: NSF Certified for Sport products, NSF GMP/cGMP claims, COAs on request, disclosed analytical testing, IFOS fish-oil verification, and repeated use of branded/bioavailability-oriented ingredients.12252627 The main cautions are not current contamination findings but historical regulatory baggage: a 2011 FDA warning letter, a 2013 undeclared-allergen recall, a 2013 Form 483 listing with inaccessible details, and old California Prop 65 activity, all heavily discounted under the 10+ year recency rule.11141819 Transparency is above average for a supplement brand because ownership, manufacturing location, and COA access are visible, but XYMOGEN still does not appear to offer a universal public lot-level COA portal and has a recent TINA.org claim-substantiation warning related to menopause marketing.1720 Value is acceptable but not budget: premium pricing is partly justified for certified and specialty formulas, but shoppers buying basic nutrients can likely find lower-cost options.252746

Quality

81 /100

Strong

Formulation

86 /100

Strong

Transparency

84 /100

Strong

Safety

76 /100

Adequate

Value

70 /100

Adequate

Sentiment

85 /100

Strong

Evidence summary

Evidence summary

XYMOGEN shows a solid quality posture with NSF Certified for Sport listings and public company disclosures, but the available evidence remains limited.

  • NSF lists XYMOGEN products in the Certified for Sport program, a strong third-party quality signal.2
  • XYMOGEN openly identifies contract manufacturing, which improves supply-chain transparency.4
  • The source set is mostly brand-owned material, so independent verification stays limited.1

Top strengths

  • Formulation quality and premium ingredient forms
  • COAs on request plus disclosed testing methods
  • NSF Certified for Sport options for athletes
  • Strong practitioner-channel reputation

Key concerns

  • No universal public COA portal found
  • Premium pricing versus commodity alternatives
  • Old FDA warning/recall/Prop 65 history remains relevant as context
  • Recent TINA.org claim-substantiation warning for menopause marketing

Badges

NSF certified Third-party tested Effective dosing Premium ingredients Research-backed Athlete-safe Fair value Transparent pricing Community favorite

Axis by axis

What the evidence shows

Quality

81/100 Strong

Net quality adjustment: +31 from a 50 baseline, implying a downstream quality score around 81. The strongest quality evidence is current NSF Certified for Sport listings, NSF GMP/cGMP claims, specific analytical testing methods, and COAs on request; the main deductions are old FDA/recall history that is heavily discounted under the 10+ year recency rule.12111426

Formulation

86/100 Strong

Net formulation adjustment: +36 from a 50 baseline, implying a downstream formulation score around 86. XYMOGEN earns strong formulation credit for sampled effective doses, branded ingredients, bioavailability technologies, and research involvement, with a small deduction for a recent claim-substantiation concern limited to menopause marketing.202122252730

Transparency

84/100 Strong

Net transparency adjustment: +34 from a 50 baseline, implying a downstream transparency score around 84. XYMOGEN is above average on COA access, ownership disclosure, manufacturing-location disclosure, and selected verifiable third-party certifications, but it does not appear to provide a line-wide public COA portal and has a recent claim-substantiation warning from TINA.org.1272026

Safety

76/100 Adequate

Net safety adjustment: -14 from a 90 baseline, implying a downstream safety score around 76. XYMOGEN’s current safety picture is not dominated by recent issues, but the brand has meaningful old regulatory history: a 2011 FDA warning letter, a 2013 undeclared-allergen recall, a 2013 Form 483 listing, and 2014 Prop 65 lead-related activity, all heavily time-discounted.11141819

Value

70/100 Adequate

Net value adjustment: +20 from a 50 baseline, implying a downstream value score around 70. XYMOGEN’s value is acceptable rather than cheap: pricing is premium, but the premium is partly justified by certifications, COA access, testing claims, and specialty ingredients, especially in fish oil, magnesium, creatine/sport, and practitioner formulas.12252627

Sentiment

85/100 Strong

Net social-sentiment adjustment: +25 from a 60 baseline, implying a downstream social score around 85. The brand is well regarded in the practitioner/integrative niche and receives positive community mentions, but broad consumer-review data is limited and employee reviews are mixed.53437384243

The rubric

How every score was built

Each axis opens at a category baseline, then moves only on dated, cited evidence — never a gut call. That is the whole difference from a star rating: every one of these 33 adjustments is a receipt you can check.

Points What moved the score
Quality baseline 50 81 Strong
+12 NSF GMP manufacturing quality signal: XYMOGEN states its GMP certification is through NSF, operates an environmentally controlled Orlando manufacturing/warehouse campus, and describes cGMP-compliant identity, purity, strength, and composition controls. Awarding mid-range +12 within the +10 to +15 NSF/USP facility-certification range because the claim is current on XYMOGEN’s site and supported by current NSF product listings, but I did not locate a separate public NSF GMP facility-directory page in the accessible search results. 1234 Current/ongoing; XYMOGEN quality pages crawled in 2026 and NSF listing current as of 2026-06-12. · full weight
+8 NSF Certified for Sport finished products: NSF’s official listing shows multiple current XYMOGEN finished products, including ATP Ignite, XymoBolX, AngiNOX Elite, OptiMag 125, Creatine, Creatine AthletiX, Electrolyte Sticks, and Omega MonoPure 1300 EC. Awarding +8 within the +5 to +10 range because the certification is strong and athlete-relevant, but it applies to a subset rather than the entire 300+ product catalog. 25 Current NSF listing dated 2026-06-12. · full weight
+10 COAs available on request for every batch: XYMOGEN says every batch of every formula has a unique certificate of analysis and provides COAs through customer service. Awarding +10 within the +8 to +12 COA-on-request quality range; not full +12 because this is request-based rather than a fully public batch portal. 1625 Current/ongoing disclosure on XYMOGEN site. · full weight
+10 Analytical testing program disclosed: XYMOGEN describes raw-material identity testing and in-house methods including HPTLC, HPLC, FTIR, and ICP-MS, plus third-party potency confirmation and external programs such as IFOS for fish oils. Awarding +10 within the +8 to +12 third-party/independent testing-disclosed range because the methods are specific and relevant to identity, potency, and contaminants. 12526 Current/ongoing disclosure, with IFOS example available for an older lot. · full weight
+4 Contaminant and heavy-metal testing signal: XYMOGEN says ingredients and finished products are tested for contaminants, NSF Certified for Sport products require contaminant/banned-substance screening, and an IFOS Omega MonoPure report shows pass results for oxidation, PCBs/dioxins, heavy metals, and label consistency. Awarding +4 within the +3 to +6 heavy-metal testing range because the strongest public proof is concentrated in fish oils and Certified for Sport SKUs rather than a full public line-wide portal. 12326 Current testing claims; IFOS lot report is historical but supports the program type. · full weight
−8 Historical FDA warning letter for CGMP and labeling/drug-claim violations: FDA’s 2011 warning letter to Atlantic Pro Nutrients dba XYMOGEN cited CGMP issues including quality-control responsibility, complaint procedures, holding/distribution procedures, returned-product procedures, and training records, plus unapproved drug claims. Base severity selected at -30 within the -25 to -35 warning-letter range because the violations were broad; temporal discount for 10+ years applies: -30 × 25% = -7.5, rounded to -8. Closeout reported in 2012 mitigates current relevance but does not erase the historical quality signal. 111213 Warning letter dated 2011-12-13; more than 10 years old; closeout reported 2012-08-21. · 25% weight
−5 Historical allergen-control lapse: XYMOGEN voluntarily recalled artriphen in 2013 after milk and soy allergens were confirmed but not declared on the label. Base severity selected at -18 within the -15 to -25 quality-complaints/contamination-control range because undeclared allergens can be serious for sensitive users; temporal discount: -18 × 25% = -4.5, rounded to -5. No allergic reactions were reported in the sources reviewed, and the company reportedly discontinued sales, tested, notified FDA, and notified physicians, which keeps the base severity below the high end. 141516 2013 recall; more than 10 years old. · 25% weight
— Not scored I did not locate a public NSF GMP facility-directory entry separate from XYMOGEN’s own NSF GMP claim, nor a public line-wide batch COA portal. Some FDA 483 details appear to be behind third-party/paywalled databases.
Formulation baseline 50 86 Strong
+10 Brand/product-involved clinical research: XYMOGEN supplied or collaborated on several research contexts, ProbioMax DF in a completed randomized ClinicalTrials.gov study with 151 enrolled participants, OncoPLEX-related broccoli extract capsules prepared by XYMOGEN in a PLOS One bioavailability study, and oral multivitamin/mineral preparations for NIH-funded TACT2. Awarding +10, below the +15 to +20 full clinical-trials range, because these are meaningful signals but not a broad set of peer-reviewed efficacy trials on commercial finished products with posted positive outcomes. 21222324 Mixed: 2014-2022 evidence; still relevant but not mostly recent. · full weight
+9 Effective-dose pattern in sampled formulas: Of 7 sampled products with usable dose/context evidence, 6 appeared plausibly aligned with clinical or category-standard dosing: Creatine/Creatine AthletiX at ~5 g per serving, Omega MonoPure using concentrated EPA/DHA fish oil, CurcuPlex directions matching cited 500-1000 mg/day curcumin trial ranges, SynovX Recovery providing 1200 mg/day chondroitin sulfate, ProbioMax DF using 100 billion CFU in a randomized trial, and S-Acetyl Glutathione supplying 200 mg per serving. Pattern calculation: 6/7 = 86% of sampled products; applying a strong but sample-limited +9 within the +10 to +15 majority-effective-dose range, reduced because this was not a comprehensive catalog audit. 22225282930 Current product pages plus older clinical registry/DRS evidence. · full weight
+10 Bioavailability and delivery technologies: sampled products use MaxSimil monoglyceride fish oil, Magtein magnesium L-threonate, Albion/TRAACS chelates, DRcaps acid-resistant capsules for S-acetyl glutathione, and high-curcuminoid CurcuPlex formatting. Awarding +10 within the +8 to +12 bioavailability-tech range because this is a recurring pattern across sampled products, not a single formula. 25272829 Current product pages and DRS documents. · full weight
+6 Branded/premium ingredients pattern: sampled products include MaxSimil, IFOS-certified fish oil, Magtein, Albion/TRAACS, CS b-Bioactive chondroitin, Shimizu Propol A glucomannan, Oralvisc, and BCM-95/curcumin-related references. Awarding +6 within the +5 to +8 branded-premium-ingredients range because the pattern is significant in sampled specialty products but not proven line-wide. 25272930313233 Current or recent product pages/DRS documents. · full weight
+3 Minimal filler pattern in sampled DRS labels: S-Acetyl Glutathione and CurcuPlex list relatively conventional inactive ingredients rather than very long filler systems; many sampled products disclose excipients plainly. Awarding +3, the low end of the +3 to +5 minimal-filler range, because the sample is limited and some products still use standard excipients such as cellulose, stearic acid, magnesium stearate, silica, and dicalcium phosphate. 2829 Current/recent DRS documents. · full weight
−2 Recent product-claim substantiation concern: TINA.org’s 2024 letter urged XYMOGEN to review menopause-related claims for Femquil and ensure compliance with FTC/FDA law. This is not an FDA warning letter or court finding, and it appears limited to one product/claim set; applying the minimum scored deduction. Base selected -8 within the claims-without-evidence range, pattern proportion estimated at roughly 25% for one product/category signal rather than line-wide practice: -8 × 25% = -2. 20 2024-10 letter; within 2 years of scoring date. · full weight
— Not scored No comprehensive line-wide label audit was possible from accessible search results. Some DRS PDFs expose supplement facts, but many catalog pages are dynamic and do not reliably render all dose details in text.
Transparency baseline 50 84 Strong
+12 COAs available on request: XYMOGEN states every batch of every formula has a unique COA and provides COAs upon request through customer service. Awarding +12 within the +10 to +15 transparency range for COAs on request; not awarding public-portal points because the evidence indicates request/QR-based access, not a universal public batch lookup portal. 162527 Current/ongoing disclosure. · full weight
+8 Third-party testing and certification disclosed with enough specificity to verify selected claims: NSF Certified for Sport listing is publicly verifiable; IFOS fish-oil testing is available for at least some lots; XYMOGEN discloses third-party potency testing. Awarding +8 within the +8 to +12 third-party-testing-disclosed range because the verification is strong for selected product categories but not equally public for every product. 12326 Current NSF listing; IFOS lot report historical; current testing claims. · full weight
+8 Ownership and key management disclosed: XYMOGEN presents itself as Blackburn family-owned, and Florida records for XYMOGEN Manufacturing identify XYMOGEN, Inc. and Blackburn family officers/managers. Awarding +8 within the +8 to +12 ownership-disclosure range because ownership/control is more visible than many private supplement companies, though full capitalization/beneficial ownership details are not public. 789 Current public filings and company page. · full weight
+6 Manufacturing location disclosed: company and public records consistently point to the Orlando, Florida campus at 6900 Kingspointe Parkway, and XYMOGEN describes its manufacturing, packaging, warehousing, and quality-control operations there. Awarding +6 within the +6 to +10 manufacturing-locations-disclosed range because the primary location is clear, but I did not locate a multi-facility audit or full supplier map. 34734 Current/ongoing. · full weight
+4 Clear access channels and consumer/practitioner disclosures: product pages show direct consumer purchasing, autoship pricing, contact details, product attachments such as Doctor Reference Sheets/COAs on some pages, and support phone/email. Awarding +4 within the +3 to +5 clear-labeling/no-hidden-terms range because the commerce flow is clearer than legacy practitioner-only access, but some label data is still embedded in images or PDFs rather than fully structured text. 52527 Current/ongoing. · full weight
−4 Recent marketing-transparency concern: TINA.org’s 2024 letter says XYMOGEN should review Femquil menopause marketing claims and notes the company received an FTC Notice of Penalty Offenses concerning substantiation of product claims in 2023. This is not a regulator’s finding against XYMOGEN for those claims, but it is a credible transparency concern. Base selected -10 within the claims-can’t-be-verified range, limited-scope pattern at 40% for one product/category claim set: -10 × 40% = -4. 20 2024-10 letter; within 2 years. · full weight
— Not scored No full supplier/country-of-origin map was located. COA access appears request-based or product/QR-based rather than a comprehensive public portal.
Safety baseline 90 76 Adequate
+4 Clean recent official-safety record signal: I found historical FDA warning/recall items, but no recent FDA warning letter or recall for XYMOGEN in the last 5 years in the sources surfaced during this investigation. Awarding +4 within the +3 to +6 clean-record range, reduced because older issues prevent a full clean-history badge and because absence of surfaced evidence is not proof of absence. 121744 No surfaced recent FDA recall/warning in the reviewed records; current through 2026 search period. · full weight
−8 2011 FDA warning letter: According to FDA-warning-letter databases and secondary reproduction of the letter, FDA cited significant dietary-supplement CGMP violations and unapproved drug claims for several products. Base severity selected -30 within the -25 to -35 range because the issues were broad, but the letter is more than 10 years old and was reportedly closed out in 2012. Recency formula: -30 × 25% = -7.5, rounded to -8. 111213 2011 warning letter; closeout reported 2012; more than 10 years old. · 25% weight
−5 2013 voluntary recall for undeclared milk and soy allergens in artriphen: base selected -18 within the -12 to -18 serious voluntary recall range because undeclared allergens can create serious/life-threatening risk for sensitive users; mitigating factors include voluntary handling, no reported allergic reactions in available sources, and old age. Recency formula: -18 × 25% = -4.5, rounded to -5. 141516 2013 voluntary recall; more than 10 years old. · 25% weight
−3 2013 FDA Form 483 listing: an accessible FDA483s listing shows an XYMOGEN inspection ending 2013-05-24, but observation details were not visible. Base selected at the low end of FDA 483 range (-10) due to missing detail, then discounted for age: -10 × 25% = -2.5, rounded to -3. This is scored cautiously because FDA 483s are regulatory safety/compliance signals, but confidence is limited. 18 2013 inspection; more than 10 years old. · 25% weight
−2 2014 California Prop 65 lead-related notices/settlement context: California Attorney General records show Prop 65 notices/complaint activity involving Atlantic Pro-Nutrients/Xymogen and lead/lead compounds in dietary supplements. Because this appears old, state-specific, and based on Prop 65 warning/reformulation/testing allegations rather than a federal contamination recall, base selected -8, allegation/status uncertainty discount 50%, then 10+ year temporal discount 25%: -8 × 50% × 25% = -1, but safety issues are always scored; applying minimum safety score of -2. 1935 2014 Prop 65 activity; more than 10 years old. · 25% weight
— Not scored FDA 483 observation details were not accessible in the sources surfaced. Some historical recall details appear in third-party FDA-data aggregators rather than full FDA pages, so those were treated cautiously.
Value baseline 50 70 Adequate
+12 Premium pricing partially justified by quality/certifications: XYMOGEN is not a budget brand, but the price premium is supported by NSF Certified for Sport products, NSF GMP/cGMP quality claims, COAs on request, specialty ingredients, and IFOS fish-oil verification for selected products. Awarding +12 within the +12 to +18 premium-justified range; not higher because the strongest public verification is not line-wide and public COAs are not universal. 12252627 Current price/product/certification evidence. · full weight
+10 Transparent pricing and autoship discount: current product pages show one-time purchase price and 10% Autoship & Save pricing; XYMOGEN’s catalog also advertises free shipping on all orders. Awarding +10 at the top of the +6 to +10 transparent-pricing range because the main pricing mechanics are visible on product pages reviewed. 252746 Current 2026 product pages. · full weight
+3 Free shipping improves realized value: XYMOGEN’s catalog pages state free shipping on all orders. Awarding +3 within the +2 to +4 shipping-threshold range because no minimum threshold was surfaced in the catalog snippet. 5 Current catalog page. · full weight
−5 Premium cost burden in sampled products: sampled current prices include Omega MonoPure 1300 EC 120 softgels at $118.99, Omega MonoPure 650 EC 60 softgels at $52.99, and OptiMag Neuro 60 servings at $84.99. These prices are premium versus mainstream commodity supplements; applying a limited -5 penalty, below the -12 to -18 overpriced range, because the sampled products use specialty forms/certifications and are not simple generics. 252746 Current 2026 product pages. · full weight
— Not scored I did not conduct a full SKU-by-SKU price-per-active-ingredient comparison across Thorne, Designs for Health, Pure Encapsulations, Nordic Naturals, and commodity brands. Dynamic pricing and practitioner discounts may change actual value.
Sentiment baseline 60 85 Strong
+12 Practitioner-channel endorsement and adoption: XYMOGEN’s own site features integrative-practitioner testimonials, PR/news sources describe practitioner-channel growth, and WholeScripts positions XYMOGEN around practitioner recommendations. Awarding +12 within the +12 to +18 authentic community/practitioner endorsement range because practitioner adoption is a core brand signal, though much of the evidence is company-controlled or trade-press rather than independent polling. 51340 Current company platform plus older trade coverage. · full weight
+8 Positive supplement-community mentions: Reddit discussions surfaced multiple positive or reputation-supporting mentions, including users naming XYMOGEN among reputable/practitioner-grade brands and a holistic nurse practitioner saying they prescribe/use XYMOGEN. Awarding +8 within the +8 to +12 community-favorite niche range because volume is moderate rather than overwhelming. 373839 Mixed 2020-2025 Reddit mentions; recent enough for sentiment but not all current. · full weight
+5 Niche athlete/fish-oil credibility: Reddit fish-oil discussions mention IFOS-certified brands and include positive mentions of XYMOGEN; official NSF/IFOS evidence supports the community perception for those SKUs. Awarding +5 because this is a niche endorsement pattern, not broad consumer dominance. 2264748 Current certifications plus recent/older community mentions. · full weight
+3 Moderate social/influencer/professional presence: XYMOGEN has an active LinkedIn presence, a Brand Ambassador page, named practitioner education/webinar content, and a professional platform ecosystem. Awarding +3 as a low-end influencer/presence credit because the presence is real but not dominant compared with mass-market influencer brands. 5104041 Current/ongoing. · full weight
−3 Mixed employee sentiment as a limited reputation drag: Indeed shows 2.8/5 across 64 reviews, while Glassdoor shows 3.3/5 across 49 reviews. This is not a direct consumer product-quality measure and does not meet the rubric’s stronger employee-complaint threshold, but it is a modest social/trust signal. Applying -3 as a low-severity adjustment. 4243 Current review pages, with reviews through 2026/2025. · full weight
— Not scored Public consumer-review volume is thinner than for mass-market brands. Reddit evidence was sampled and should be treated as directional, not statistically representative.

Best for

  • Patients using an integrative, functional, or longevity-oriented practitioner who wants protocol-based products with COA access, premium forms, and practitioner support tools.[^5][^40]
  • Athletes or highly contamination-conscious users choosing the specific XYMOGEN SKUs that are NSF Certified for Sport, not assuming the entire catalog has that certification.[^2][^3]
  • Shoppers willing to pay premium prices for specialty forms such as MaxSimil fish oil, Magtein/TRAACS magnesium, IFOS fish oil documentation, or other branded ingredients.[^25][^26][^27]

Skip if

  • You require a public, line-wide COA portal with instant lot lookup for every bottle; XYMOGEN states COAs are available on request, but I did not find a universal public portal.[^1][^6]
  • You are shopping for the lowest cost per serving on basic nutrients; sampled XYMOGEN products are priced in the premium practitioner tier.[^25][^27][^46]
  • You have severe milk/soy allergy concerns and want a brand with no historical allergen-labeling issues at all; XYMOGEN’s artriphen undeclared milk/soy recall is old, but it did occur.[^14][^15]

Questions

What shoppers ask about XYMOGEN

Is XYMOGEN a reputable brand?

Yes, XYMOGEN appears reputable in the practitioner-grade supplement category: it discloses COAs on request, lists specific analytical testing methods, has current NSF Certified for Sport products, and uses premium forms in sampled formulas.122527 The caveat is that it has old regulatory history, a 2011 FDA warning letter and a 2013 allergen recall, so shoppers should verify the specific product’s COA/certification rather than relying on brand reputation alone.1114

What is the most trustworthy vitamin company?

There is no single universally accepted “most trustworthy” vitamin company; the safest way to judge trust is to look for independent certifications, accessible COAs, clear ownership, strong testing, and a clean recent safety record.123 XYMOGEN meets several of those criteria, especially for COA access and certified sport products, but it does not appear to offer a universal public COA portal and has old regulatory history.11114

What is XYMOGEN good for?

XYMOGEN is best suited for practitioner-guided supplement protocols, specialty formulas, fish oil/magnesium/probiotic products, and athletes choosing the specific SKUs that are NSF Certified for Sport.2252740 It is less ideal if you want the cheapest basic vitamin or insist on public lot-level COAs for every product.125

Is XYMOGEN a US company?

Yes. XYMOGEN is headquartered in Orlando, Florida, and Florida public records list XYMOGEN Manufacturing, LLC at 6900 Kingspointe Parkway, Orlando, FL.734 The company also describes itself as Blackburn family-owned and operating a large Orlando campus.8

What is the #1 most trustworthy vitamin company?

No evidence-based source ranks a single permanent “#1” trustworthy vitamin company across all products and categories. For any brand, including XYMOGEN, verify the exact product’s third-party certification, COA access, active ingredient dose, and recent recall/warning history before buying.121744

What vitamin helps crepey skin after 50?

Vitamin C is the clearest vitamin-related answer because NIH says vitamin C is required for collagen biosynthesis, but it will not reverse crepey skin by itself if the issue is aging, sun damage, weight change, or low skin hydration.45 Collagen peptides, not a vitamin, have some randomized-trial evidence for improving skin elasticity in post-menopausal or middle-aged women, but results vary and supplements should be treated as supportive rather than curative.52

Sources

  1. 1. Our Quality | XYMOGEN (2026)
  2. 2. NSF Product and Service Listings — XYMOGEN INC. Certified for Sport (2026)
  3. 3. Certified for Sport Program | NSF (2026)
  4. 4. Contract Manufacturing | XYMOGEN (2026)
  5. 5. XYMOGEN — Premium Dietary Supplements for Health & Wellness (2026)
  6. 6. Omega MonoPure 1300 EC Product Page | XYMOGEN (2026)
  7. 7. Florida Division of Corporations — XYMOGEN Manufacturing, LLC (2026)
  8. 8. A Family Owned Supplement Company You Can Trust | XYMOGEN (2026)
  9. 9. XYMOGEN LinkedIn Company Profile (2026)
  10. 10. Professionals / Brand Ambassador and practitioner resources | XYMOGEN (2026)
  11. 11. FDA Warns XYMOGEN of Manufacturing and Labeling Violations — ConsumerLab (2012)
  12. 12. FDA Warning Letters Database for Dietary Supplements — Atlantic Pro Nutrients dba XYMOGEN (2026)
  13. 13. Practitioner channel specialist Xymogen continues strong growth curve, CEO says — NutraIngredients-USA (2015)
  14. 14. XYMOGEN Recalls Joint Health Supplement — SupplySide Supplement Journal (2013)
  15. 15. Atriphen dietary supplement recall — Safety Alert Registry (2013)
  16. 16. Joint Health Supplement Recalled for Undeclared Allergens — ConsumerLab (2013)
  17. 17. Recalls, Market Withdrawals, & Safety Alerts | FDA (2026)
  18. 18. Xymogen, Inc. FDA 483s listing — FDA483s.com (2025)
  19. 19. California Prop 65 60-Day Notice 2014-00581 — Atlantic Pro-Nutrients/Xymogen (2014)
  20. 20. Truth in Advertising letter to XYMOGEN regarding menopause supplements (2024)
  21. 21. Sulforaphane Bioavailability from Glucoraphanin-Rich Broccoli — PLOS One (2015)
  22. 22. ClinicalTrials.gov NCT01445704 — Use of Probiotics to Aid in Weight Loss (2014)
  23. 23. XYMOGEN to supply multivitamin preparation for TACT2 — PRNewswire (2016)
  24. 24. The Trial to Assess Chelation Therapy 2 (TACT2): Rationale and Design — PMC (2022)
  25. 25. Omega MonoPure 1300 EC Product Page | XYMOGEN (2026)
  26. 26. IFOS Xymogen Omega MonoPure 1300 EC Lot Report (2018)
  27. 27. OptiMag Neuro Mixed Berry Product Page | XYMOGEN (2026)
  28. 28. S-Acetyl Glutathione DRS | XYMOGEN (2023)
  29. 29. CurcuPlex-95 DRS | XYMOGEN (2022)
  30. 30. SynovX Recovery Product Page — Agape Nutrition (2026)
  31. 31. OptiFiber Lean Product Page — Agape Nutrition (2026)
  32. 32. SynovX Metabolic Product Page — Agape Nutrition (2026)
  33. 33. MitoPrime Product Page — Agape Nutrition (2026)
  34. 34. XYMOGEN, Inc. BBB Business Profile (2026)
  35. 35. California Prop 65 settlement PDF 2014-00581S4193 (2015)
  36. 36. Atlantic Pro Nutrients dba XYMOGEN food recalls in 2014 — BeautifyData (2026)
  37. 37. Reddit r/Supplements — Xymogen? (2020)
  38. 38. Reddit r/Supplements — supplement stack recommendation mentioning XYMOGEN (2025)
  39. 39. Reddit r/Supplements — most trustworthy supplement brand discussion (2025)
  40. 40. WholeScripts FAQ (2025)
  41. 41. Private Label | XYMOGEN (2026)
  42. 42. Working at XYMOGEN — Indeed Reviews (2026)
  43. 43. Xymogen Reviews — Glassdoor (2025)
  44. 44. openFDA Food Enforcement API overview (2026)
  45. 45. Vitamin C Fact Sheet — NIH Office of Dietary Supplements (2026)
  46. 46. Omega MonoPure 650 EC Product Page | XYMOGEN (2026)
  47. 47. Reddit r/Supplements — IFOS/fish-oil discussion mentioning XYMOGEN (2023)
  48. 48. Reddit r/Supplements — omega-3 quality discussion mentioning XYMOGEN (2026)
  49. 49. Reddit r/HistamineIntolerance — DAO supplement discussion mentioning HistDAO by XYMOGEN (2025)
  50. 50. Reddit r/HistamineIntolerance — DAO supplement reaction discussion mentioning XYMOGEN (2024)
  51. 51. Influenster — Xymogen reviews (2026)
  52. 52. Four-weeks daily intake of oral collagen hydrolysate — PubMed (2020)

Recalibrated Jun 14, 2026 · 33 scored adjustments · 46 distinct citations across 52 sources

Want personalized recommendations?

Show me what works for me